Digestive

Lundquist Investigator Dr. Yoshihara Awarded $3 Million NIH R01 Grant for Diabetes Stem Cell Therapy Research

Retrieved on: 
Monday, April 1, 2024
TLI, Diabetes, Immunosuppression, Type 1, Research, Kidney, Hope, Doctor of Philosophy, NIH, Type 1 diabetes, NIDDK, Bangladesh Technical Education Board, UCLA, Digestive, Health, Cell, Organoid, Type 2, Medical device

This prestigious NIH R01 grant, known for its rigorous peer-review process, is dedicated to advancing stem cell therapy research for treating diabetes.

Key Points: 
  • This prestigious NIH R01 grant, known for its rigorous peer-review process, is dedicated to advancing stem cell therapy research for treating diabetes.
  • Insulin-dependent diabetes, including autoimmune Type 1 and stress-induced Type 2, presents a significant health burden, often necessitating lifelong insulin therapy and glucose monitoring.
  • Dr. Yoshihara's research focuses on the potential of human pluripotent stem cells (hPSCs) to create functional islet cells.
  • “Despite significant progress in stem cell-derived mini-organ technologies, we are still challenged by their functional immaturity and variability,” said Dr. Yoshihara.

FORTY-THREE PHYSICIANS FROM UNITED DIGESTIVE PARTNER PRACTICES NAMED CASTLE CONNOLLY TOP DOCTORS 2024

Retrieved on: 
Tuesday, April 9, 2024
Education, Journal, Faculty, Castle Connolly Medical, Gastroenterology, Medical research, Digestive, Physician, Health, Nursing

ATLANTA, April 9, 2024 /PRNewswire/ -- Forty-three physicians from six partner practices of United Digestive have been honored by Castle Connolly as Top Doctors for 2024 for their demonstrated excellence in clinical care, among many other factors.

Key Points: 
  • ATLANTA, April 9, 2024 /PRNewswire/ -- Forty-three physicians from six partner practices of United Digestive have been honored by Castle Connolly as Top Doctors for 2024 for their demonstrated excellence in clinical care, among many other factors.
  • Recipients of the Top Doctors distinction represent the top seven percent of all practicing physicians in the United States.
  • "We are incredibly proud of our 43 physicians who have been recognized as Castle Connolly Top Doctors for 2024," said Dr. Neal C. Patel, CEO of United Digestive.
  • For more information about United Digestive, its partner practices, and Top Doctors recipients, please visit www.uniteddigestive.com .

Mahana Therapeutics Acquires Cara Care to Become a Global Leader in the Digital Treatment of Chronic Conditions

Retrieved on: 
Tuesday, March 12, 2024
Software, Biotechnology, Pharmaceutical, General Health, Health, Health Technology, Technology, Apps, Applications, Partnership, Patient, Irritable bowel syndrome, Acquisition, CBT, Heartburn, Digestate, IBD, Bayer, Patient satisfaction, Cognitive behavioral therapy, Therapy, IBS, Lux Capital, FDA, Digestive, Coeliac disease, Gesellschaft mit beschränkter Haftung, Nursing

Mahana Therapeutics, a leading provider of digital chronic condition management programs, announced today that it has acquired Berlin-based HiDoc Technologies GmbH, operating as Cara Care, a leader in digital digestive healthcare.

Key Points: 
  • Mahana Therapeutics, a leading provider of digital chronic condition management programs, announced today that it has acquired Berlin-based HiDoc Technologies GmbH, operating as Cara Care, a leader in digital digestive healthcare.
  • The acquisition of Cara Care is expected to accelerate Mahana’s market entry in Europe where the reimbursement of digital programs is outpacing the United States.
  • Cara Care’s IBS prescription-based digital program is currently being prescribed, and reimbursed, to thousands of patients in Germany.
  • "The combination of Mahana and Cara Care is an incredible opportunity to bring together our complementary expertise in chronic digestive health conditions and create a one-of-a-kind global offering of digital programs across the Digestive, Hearing, Dermatology, and Women’s Health markets.

RSNA: Early Coronary Disease, Impaired Heart Function Found in Asymptomatic People with HIV

Retrieved on: 
Thursday, April 4, 2024
Biomedicine, Cardiovascular disease, MRI, Coronary artery disease, HIV, Didanosine, Viral load, Education, Patient, Facial muscles, Research, Kidney, University, Death, Physical examination, NIH, Society, Life expectancy, Risk, Moyamoya disease, OAK, World Health Organization, RSNA, DRS, Heart, Radiation, Bangladesh Technical Education Board, Digestive, Synthetic control method, Health, Person, Pharmaceutical industry

OAK BROOK, Ill., April 4, 2024 /PRNewswire-PRWeb/ -- A new study found increased coronary vessel wall thickness that was significantly associated with impaired diastolic function in asymptomatic, middle-aged individuals living with HIV. The study was published today in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of North America (RSNA).

Key Points: 
  • A new study found increased coronary vessel wall thickness that was significantly associated with impaired diastolic function in asymptomatic, middle-aged individuals living with HIV.
  • The ability to detect early coronary artery disease in persons living with HIV and potentially prevent detrimental effects on the heart muscle is important.
  • This research shows the impact of HIV on developing subtle subclinical coronary artery disease and its effects on heart function.
  • "This research shows the impact of HIV on developing subtle subclinical coronary artery disease and its effects on heart function."

AI Can Speed Design of Health Software

Retrieved on: 
Wednesday, March 6, 2024
Software design, Engineering, MCIT, Internet, Research, Doctor of Philosophy, Medicine, Population health, Artificial intelligence, Multimedia, Health, Digestive, Language, Exercise, Learning, ChatGPT, Synthetic media, NYU, Kidney, Nursing, NYU Langone Health, Patient, Journal, Intuition, Physician, PAMS, Software, Medical device

NEW YORK, March 6, 2024 /PRNewswire/ --Publishing online March 6 in the Journal of Medical Internet Research, the study examined the capabilities of a form of artificial intelligence (AI) called generative AI or GenAI, which predicts likely options for the next word in any sentence based on how billions of people used words in context on the internet. A side effect of this next-word prediction is that the generative AI "chatbots" like chatGPT can generate replies to questions in realistic language, and produce clear summaries of complex texts.

Key Points: 
  • Led by researchers at NYU Langone Health, the current paper explores the application of ChatGPT to the design of a software program that uses text messages to counter diabetes by encouraging patients to eat healthier and get exercise.
  • The team tested whether AI-enabled interchanges between doctors and software engineers could hasten the development of such a personalized automatic messaging system ( PAMS ).
  • If this proves to be effective at scale it could revolutionize healthcare software design."
  • AI could take software design only so far before human software developers were needed for final code generation, but the overall process was greatly accelerated, say the authors.

Westat Awarded Contract to Continue Supporting the PATH Study

Retrieved on: 
Wednesday, February 21, 2024
Human services, Bangladesh Technical Education Board, PATH, Molina Healthcare, Research, Doctor of Philosophy, CTP, National Institutes of Health, NIH, FDA, Food, Data collection, Digestive, National Cancer Institute, Heated tobacco product, Lung, Kidney, Food and Drug Administration, Center for Tobacco Products, Federal, Public, Knowledge, National library, Behavior, Social science, Partnership, Pharmaceutical industry

ROCKVILLE, Md., Feb. 21, 2024 /PRNewswire/ -- The National Institutes of Health's (NIH's) National Institute on Drug Abuse (NIDA) and the U.S. Food and Drug Administration's (FDA's) Center for Tobacco Products (CTP) have announced the award of a third contract to Westat to continue to support the Population Assessment of Tobacco and Health (PATH) Study. Westat has supported the study since its inception in 2011.

Key Points: 
  • Westat is committed to continuing the trusted partnership with NIH/NIDA and FDA/CTP on the Population Assessment of Tobacco and Health (PATH) Study to understand tobacco use patterns and impacts on public health.
  • Westat has supported the study since its inception in 2011.
  • The PATH Study is a uniquely large, long-term study of tobacco use and health in the United States.
  • "Our work will build on the knowledge we have gained during the past 12 years of supporting the PATH Study and a foundation of over 35 years of tobacco research," notes Charles Carusi, PhD , a Westat Vice President and the project director for the PATH Study.

NYU Langone Health Awarded $13 Million to Create National Center to Promote Diabetes Equity Research

Retrieved on: 
Tuesday, February 6, 2024
Olive, Partnership, NYU Langone Health, Digestive, Family, Kidney failure, Public, Prediabetes, Nerve, Research, Health equity, MD, Caregiver, Patient, UCLA, Kidney, Paratriathlon, Olive View–UCLA Medical Center, School, Organization, American Diabetes Association, Social medicine, MPH, Diabetes, Education, AUC, Trust, Bangladesh Technical Education Board, Community, Type 2 diabetes, Workforce, African Americans, Pharmaceutical industry

To generate more community-engaged diabetes research, the National Institute of Diabetes and Digestive and Kidney Diseases, a division of the National Institutes of Health, has pledged $13 million to NYU Langone Health, Albert Einstein School of Medicine/Montefiore Health System, and UCLA School of Medicine to create the National Center for Engagement in Diabetes Equity Research (CEDER), the first of its kind.

Key Points: 
  • To generate more community-engaged diabetes research, the National Institute of Diabetes and Digestive and Kidney Diseases, a division of the National Institutes of Health, has pledged $13 million to NYU Langone Health, Albert Einstein School of Medicine/Montefiore Health System, and UCLA School of Medicine to create the National Center for Engagement in Diabetes Equity Research (CEDER), the first of its kind.
  • Co-led by Nadia Islam, PhD, associate professor in the Institute for Excellence in Health Equity at NYU Langone, CEDER will create a centralized national infrastructure designed to foster community engagement and participation of diverse populations in Type 2 diabetes research.
  • "It is our hope that everyone committed to advancing equity in diabetes research and care can access the support and mentorship they need."
  • CEDER is funded by the National Institute of Diabetes and Digestive and Kidney Diseases.

Supportive, Stable Caregiving in Childhood Protects Heart Health in Adulthood

Retrieved on: 
Tuesday, January 23, 2024
CARDIA, Hope, Pediatrics, American Heart Association, Death, Population health, NYU Langone Health, Risk, Research, Overalls, Physiology, Health, Life, Smoking, Diet, CVD, University, Lipid, Behavior, Ageing, PHD, MHS, NYU, Safety, White, Caregiver, Cardiovascular disease, Child, University of California, Circulation (journal), Popliteal artery entrapment syndrome, University of Pennsylvania, Kidney, CVH, MPH, Black, Endocrine Society, Digestive, Saint Andrew's Society, Blood pressure, Lung

New research, however, shows that receiving warmth from a caregiver during childhood protects cardiovascular health later in life, according to a study led by NYU Grossman School of Medicine and The Ohio State University Wexler Medical Center.

Key Points: 
  • New research, however, shows that receiving warmth from a caregiver during childhood protects cardiovascular health later in life, according to a study led by NYU Grossman School of Medicine and The Ohio State University Wexler Medical Center.
  • "At the same time, our findings show that adversity in early childhood does not equal destiny.
  • While adverse childhood family environments were associated with lower odds of cardiovascular health in adulthood, our findings suggest that supportive and, importantly, stable caregiving may have a stronger influence on later heart health than early adversity."
  • The hope, says Ortiz, is that this study offers insight into how supporting healthy, both supportive and stable, caregiving relationships in childhood can offer greater attainment of CVH at a population level.

AnX Robotica Announces FDA Clearance for ProScan™: A Groundbreaking AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy

Retrieved on: 
Wednesday, January 3, 2024
Endoscopy, Gastrointestinal bleeding, Multimedia, Physician, Marketing, FDA, ProScan, Digestive, Health, Agostino Gemelli University Policlinic, Patient, Robotics, Medical device

Through the rigorous De Novo Submission Process, the FDA has granted clearance for ProScan, making it the first AI Assisted Reading Tool designed to aid small bowel capsule endoscopy reviewers for adult patients in whom the capsule endoscopy images were obtained for suspected small bowel bleeding.

Key Points: 
  • Through the rigorous De Novo Submission Process, the FDA has granted clearance for ProScan, making it the first AI Assisted Reading Tool designed to aid small bowel capsule endoscopy reviewers for adult patients in whom the capsule endoscopy images were obtained for suspected small bowel bleeding.
  • First AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy.
  • ProScan software, an artificial intelligent (AI) assisted reading tool, leverages cutting-edge technology to revolutionize the field of gastroenterology.
  • "We are delighted to announce the FDA clearance of NaviCam ProScan, a transformative AI Assisted Reading Tool that addresses a critical need in the realm of small bowel capsule endoscopy," said Stu Wildhorn, Vice President of Marketing and Product Management at AnX Robotica.

Enable Biosciences Receives $3M Phase IIB SBIR Award from NIDDK for Advanced T1D Testing Technology

Retrieved on: 
Tuesday, December 19, 2023
Carolyn Bertozzi, Autoantibody, Risk, SBIR, Validation, FDA, Digestive, Disease, Kidney, SAN, Doctor of Philosophy, NIDDK, Type 1 diabetes, ADAP, Safety

A key objective of this funding is to pursue FDA clearance for the T1D test, a critical step towards commercialization.

Key Points: 
  • A key objective of this funding is to pursue FDA clearance for the T1D test, a critical step towards commercialization.
  • Dr. Jason Tsai, PhD, Chief Technical Officer at Enable Biosciences, shared his enthusiasm: "This Phase IIB SBIR award from NIDDK is a testament to our dedication to transforming T1D testing.
  • The NIDDK's support is pivotal for Enable Biosciences in its pursuit of FDA clearance for its innovative T1D test.
  • For more information about Enable Biosciences and their cutting-edge approach to T1D testing, visit www.enablebiosciences.com or contact their media team for further details and inquiries.